更新的奥地利转移性三阴性乳腺癌治疗算法。
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer.
发表日期：2023 Sep 08
作者：
Rupert Bartsch, Gabriel Rinnerthaler, Edgar Petru, Daniel Egle, Michael Gnant, Marija Balic, Thamer Sliwa, Christian Singer
来源：
Brain Structure & Function
摘要：
近期诊断出的乳腺癌患者中，约有15%缺乏激素受体表达以及HER2过表达和/或HER2/neu基因扩增。这种乳腺癌亚型被称为三阴性乳腺癌（Triple Negative Breast Cancer，TNBC），并且患者的局部和远距离复发风险明显增加。与其他乳腺癌亚型相比，TNBC存在更高的内脏和脑转移率。大多数TNBC的转移在乳腺癌初诊后三年内被诊断出。在过去的二十年中，激素受体阳性和人表皮生长因子受体2（HER2）阳性疾病取得了重大进展，但对于三阴性乳腺癌（TNBC）患者的预后仅有有限的改善。因此，一组奥地利乳腺癌专家召开了专家会议，以建立已有TNBC治疗的全面临床风险-效益概况，并讨论sacituzumab govitecan在治疗三阴性乳腺癌患者中的作用。© 2023. 作者。
Approximately 15% of newly diagnosed breast cancer patients have neither hormone receptors expression nor HER2 overexpression and/or HER2/neu gene amplification. This subtype of breast cancer is known as Triple Negative Breast Cancer (TNBC), and carries a significantly elevated risk of local and distant recurrence. In comparison with other breast cancer subtypes, there is a higher rate of visceral and brain metastases. The majority of metastases of TNBC are diagnosed within three years after initial breast cancer diagnosis. While there have been major advances in hormone-receptor- positive and in human epidermal growth factor receptor 2 (HER2)-positive disease over the past two decades, only limited improvements in outcomes for patients with triple negative breast cancer (TNBC) have been observed. A group of Austrian breast cancer specialists therefore convened an expert meeting to establish a comprehensive clinical risk-benefit profile of available mTNBC therapies and discuss the role sacituzumab govitecan may play in the treatment algorithm of the triple-negative breast cancer patients.© 2023. The Author(s).